Replidyne Completes $62.5 Million Financing - Henry Wendt Joins Board of Directors

Sep 08, 2005, 01:00 ET from Replidyne, Inc.

    LOUISVILLE, Colo., Sept. 8 /PRNewswire/ -- Replidyne, Inc., a privately
 held biopharmaceutical company focused on the discovery and development of new
 anti-infective drugs, announced today that it has raised $62.5 million in a
 Series D financing led by several large institutional investors, including new
 investors Duquesne Capital Management, Healthcare Investment Partners and MDS
 Life Sciences Technology II funds (served by MDS Capital Corp.).  Also
 participating in this financing round were existing investors HealthCare
 Ventures, TPG Ventures, Morgenthaler Ventures, Perseus-Soros BioPharmaceutical
 Fund, Sequel Venture Partners, Temasek Holdings Pte Ltd and Quintiles
 Transnational.  Aquilo Partners, Inc. served as the exclusive placement agent
 for Replidyne.
     Additionally, the Company announced that Henry Wendt, Founder and Managing
 Partner of Healthcare Investment Partners and former Chairman and Chief
 Executive Officer of SmithKline Beckman prior to its merger with Beecham, has
 joined Replidyne's Board of Directors.
     "The strong interest from such high-quality investors validates our
 confidence in the potential of our lead product candidate, faropenem
 medoxomil, and the ability of a superb team to drive the product to approval
 and commercialization," said Kenneth J. Collins, Replidyne's President and
 Chief Executive Officer.  "The proceeds from this offering are expected to
 carry us through the launch of faropenem for respiratory tract infections and
 will also allow us to move REP8839, a topical antibiotic being developed to
 treat infections caused by antibiotic-resistant bacteria such as MRSA, into
 clinical trials.  We are pleased with the enthusiasm of our new investors as
 well as with the commitment shown to the Company by our existing investors.
 Additionally, we are excited that Henry Wendt will join our Board of
 Directors.  Henry is one of the most experienced and respected pharmaceutical
 executives in the country and we will benefit greatly from his broad industry
     Replidyne's lead product, faropenem medoxomil, is an orally available
 antibiotic for treatment of community acquired infections such as respiratory
 tract infections (RTIs).  Replidyne expects to file a New Drug Application
 (NDA) in multiple indications for faropenem in late 2005 and, if approved by
 the FDA, to launch the product in late 2006.  Faropenem has been tested for
 safety and efficacy in nine pivotal Phase III clinical trials against RTIs in
 more than 3,400 patients.  If approved, faropenem would be the first oral
 antibiotic of the penem class to be marketed in the United States.  Penems are
 a sub-class of beta-lactams, the most widely prescribed class of antibiotics.
 Replidyne is also developing the product for additional adult and pediatric
     About Replidyne, Inc.
     Replidyne is a biopharmaceutical company focused on developing and
 commercializing innovative anti-infective products.  In addition to
 preparations for an NDA for faropenem, Replidyne's current development
 programs include higher dose/shorter course faropenem, additional adult and
 pediatric indications for faropenem, and topical applications of REP8839.
 Replidyne also maintains a research team focused on developing additional drug
 candidates, including a preclinical program directed to inhibitors of
 bacterial DNA replication.  For additional information about Replidyne, please

SOURCE Replidyne, Inc.